336 related articles for article (PubMed ID: 26505831)
1. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases.
Kumar A; Singh UK; Kini SG; Garg V; Agrawal S; Tomar PK; Pathak P; Chaudhary A; Gupta P; Malik A
Future Med Chem; 2015; 7(15):2065-86. PubMed ID: 26505831
[TBL] [Abstract][Full Text] [Related]
2. Conflicting evidence for the role of JNK as a target in breast cancer cell proliferation: Comparisons between pharmacological inhibition and selective shRNA knockdown approaches.
Wood RA; Barbour MJ; Gould GW; Cunningham MR; Plevin RJ
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417765
[TBL] [Abstract][Full Text] [Related]
3. JNK signaling as a target for anticancer therapy.
Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Narumi A; Konno H; Abdel-Aziz M
Pharmacol Rep; 2021 Apr; 73(2):405-434. PubMed ID: 33710509
[TBL] [Abstract][Full Text] [Related]
4. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
5. JNK signalling in cancer: in need of new, smarter therapeutic targets.
Bubici C; Papa S
Br J Pharmacol; 2014 Jan; 171(1):24-37. PubMed ID: 24117156
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
Messoussi A; Feneyrolles C; Bros A; Deroide A; Daydé-Cazals B; Chevé G; Van Hijfte N; Fauvel B; Bougrin K; Yasri A
Chem Biol; 2014 Nov; 21(11):1433-43. PubMed ID: 25442375
[TBL] [Abstract][Full Text] [Related]
7. JNK signalling: a possible target to prevent neurodegeneration.
Borsello T; Forloni G
Curr Pharm Des; 2007; 13(18):1875-86. PubMed ID: 17584114
[TBL] [Abstract][Full Text] [Related]
8. JNK Signaling Pathway Involvement in Spinal Cord Neuron Development and Death.
Schellino R; Boido M; Vercelli A
Cells; 2019 Dec; 8(12):. PubMed ID: 31817379
[TBL] [Abstract][Full Text] [Related]
9. JNK3 as a therapeutic target for neurodegenerative diseases.
Antoniou X; Falconi M; Di Marino D; Borsello T
J Alzheimers Dis; 2011; 24(4):633-42. PubMed ID: 21321401
[TBL] [Abstract][Full Text] [Related]
10. The JNK signal transduction pathway.
Weston CR; Davis RJ
Curr Opin Cell Biol; 2007 Apr; 19(2):142-9. PubMed ID: 17303404
[TBL] [Abstract][Full Text] [Related]
11. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
12. Role of the JNK pathway in human diseases.
Sabapathy K
Prog Mol Biol Transl Sci; 2012; 106():145-69. PubMed ID: 22340717
[TBL] [Abstract][Full Text] [Related]
13. SK-N-MC cell death occurs by distinct molecular mechanisms in response to hydrogen peroxide and superoxide anions: involvements of JAK2-STAT3, JNK, and p38 MAP kinases pathways.
Moslehi M; Yazdanparast R
Cell Biochem Biophys; 2013 Jul; 66(3):817-29. PubMed ID: 23417568
[TBL] [Abstract][Full Text] [Related]
14. Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies.
Davies C; Tournier C
Biochem Soc Trans; 2012 Feb; 40(1):85-9. PubMed ID: 22260670
[TBL] [Abstract][Full Text] [Related]
15. JNK inhibitors as anti-inflammatory and neuroprotective agents.
Graczyk PP
Future Med Chem; 2013 Apr; 5(5):539-51. PubMed ID: 23573972
[TBL] [Abstract][Full Text] [Related]
16. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.
Bogoyevitch MA; Ngoei KR; Zhao TT; Yeap YY; Ng DC
Biochim Biophys Acta; 2010 Mar; 1804(3):463-75. PubMed ID: 19900593
[TBL] [Abstract][Full Text] [Related]
17. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.
Bogoyevitch MA
Bioessays; 2006 Sep; 28(9):923-34. PubMed ID: 16937364
[TBL] [Abstract][Full Text] [Related]
18. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.
Mehan S; Meena H; Sharma D; Sankhla R
J Mol Neurosci; 2011 Mar; 43(3):376-90. PubMed ID: 20878262
[TBL] [Abstract][Full Text] [Related]
19. Cerebral ischemia provokes a profound exchange of activated JNK isoforms in brain mitochondria.
Zhao Y; Herdegen T
Mol Cell Neurosci; 2009 Jun; 41(2):186-95. PubMed ID: 19289169
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of astrocyte activation by TAT-mediated delivery of a peptide JNK inhibitor.
Kang WH; Simon MJ; Gao S; Banta S; Morrison B
J Neurotrauma; 2011 Jul; 28(7):1219-28. PubMed ID: 21510821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
